120 related articles for article (PubMed ID: 22645176)
1. Survivin is highly expressed in CD34(+)38(-) leukemic stem/progenitor cells and predicts poor clinical outcomes in AML.
Carter BZ; Qiu Y; Huang X; Diao L; Zhang N; Coombes KR; Mak DH; Konopleva M; Cortes J; Kantarjian HM; Mills GB; Andreeff M; Kornblau SM
Blood; 2012 Jul; 120(1):173-80. PubMed ID: 22645176
[TBL] [Abstract][Full Text] [Related]
2. Highly phosphorylated FOXO3A is an adverse prognostic factor in acute myeloid leukemia.
Kornblau SM; Singh N; Qiu Y; Chen W; Zhang N; Coombes KR
Clin Cancer Res; 2010 Mar; 16(6):1865-74. PubMed ID: 20215543
[TBL] [Abstract][Full Text] [Related]
3. Functional proteomic profiling of AML predicts response and survival.
Kornblau SM; Tibes R; Qiu YH; Chen W; Kantarjian HM; Andreeff M; Coombes KR; Mills GB
Blood; 2009 Jan; 113(1):154-64. PubMed ID: 18840713
[TBL] [Abstract][Full Text] [Related]
4. The multi-CDK inhibitor dinaciclib reverses bromo- and extra-terminal domain (BET) inhibitor resistance in acute myeloid leukemia via inhibition of Wnt/β-catenin signaling.
Marr AR; Halpin M; Corbin DL; Asemelash Y; Sher S; Gordon BK; Whipp EC; Mitchell S; Harrington BK; Orwick S; Benrashid S; Goettl VM; Yildiz V; Mitchell AD; Cahn O; Mims AS; Larkin KTM; Long M; Blachly J; Woyach JA; Lapalombella R; Grieselhuber NR
Exp Hematol Oncol; 2024 Mar; 13(1):27. PubMed ID: 38438856
[TBL] [Abstract][Full Text] [Related]
5. Exploring the Potential of siRNA Delivery in Acute Myeloid Leukemia for Therapeutic Silencing.
Ubeda Gutierrez AM; Remant Bahadur KC; Brandwein J; Uludağ H
Nanomaterials (Basel); 2023 Dec; 13(24):. PubMed ID: 38133064
[TBL] [Abstract][Full Text] [Related]
6. Modern Risk Stratification of Acute Myeloid Leukemia in 2023: Integrating Established and Emerging Prognostic Factors.
Boscaro E; Urbino I; Catania FM; Arrigo G; Secreto C; Olivi M; D'Ardia S; Frairia C; Giai V; Freilone R; Ferrero D; Audisio E; Cerrano M
Cancers (Basel); 2023 Jul; 15(13):. PubMed ID: 37444622
[TBL] [Abstract][Full Text] [Related]
7. A novel stemness classification in acute myeloid leukemia by the stemness index and the identification of cancer stem cell-related biomarkers.
Huang Y; Zhang Z; Sui M; Li Y; Hu Y; Zhang H; Zhang F
Front Immunol; 2023; 14():1202825. PubMed ID: 37409118
[TBL] [Abstract][Full Text] [Related]
8. Development of a cancer cells self‑activating and miR‑125a‑5p expressing poly‑pharmacological nanodrug for cancer treatment.
Chang YC; Shieh MC; Chang YH; Huang WL; Su WC; Cheng FY; Cheung CHA
Int J Mol Med; 2022 Aug; 50(2):. PubMed ID: 35703361
[TBL] [Abstract][Full Text] [Related]
9. A Review of the Current Impact of Inhibitors of Apoptosis Proteins and Their Repression in Cancer.
Cetraro P; Plaza-Diaz J; MacKenzie A; Abadía-Molina F
Cancers (Basel); 2022 Mar; 14(7):. PubMed ID: 35406442
[TBL] [Abstract][Full Text] [Related]
10. Antigen-Specific TCR-T Cells for Acute Myeloid Leukemia: State of the Art and Challenges.
Kang S; Li Y; Qiao J; Meng X; He Z; Gao X; Yu L
Front Oncol; 2022; 12():787108. PubMed ID: 35356211
[TBL] [Abstract][Full Text] [Related]
11. T-cell-based immunotherapy of acute myeloid leukemia: current concepts and future developments.
Daver N; Alotaibi AS; Bücklein V; Subklewe M
Leukemia; 2021 Jul; 35(7):1843-1863. PubMed ID: 33953290
[TBL] [Abstract][Full Text] [Related]
12. Regulation of Cellular and Cancer Stem Cell-Related Putative Gene Expression of Parental and CD44
Koh MZ; Ho WY; Yeap SK; Ali NM; Boo L; Alitheen NB
Pharmaceuticals (Basel); 2021 Apr; 14(5):. PubMed ID: 33919109
[TBL] [Abstract][Full Text] [Related]
13. Expression and clinical correlation of Survivin and PTEN in gastric cancer patients.
Yusufu A; Tuerdi R; Redati D; Rehemutula A; Zhao ZL; Wang HJ
Oncol Lett; 2020 Dec; 20(6):297. PubMed ID: 33101491
[TBL] [Abstract][Full Text] [Related]
14. Emerging Importance of Survivin in Stem Cells and Cancer: the Development of New Cancer Therapeutics.
Warrier NM; Agarwal P; Kumar P
Stem Cell Rev Rep; 2020 Oct; 16(5):828-852. PubMed ID: 32691369
[TBL] [Abstract][Full Text] [Related]
15. Plausibility of trophoblastic-like regulation of cancer tissue.
Piechowski J
Cancer Manag Res; 2019; 11():5033-5046. PubMed ID: 31213916
[No Abstract] [Full Text] [Related]
16. T-Cell Receptor-Based Immunotherapy for Hematologic Malignancies.
Biernacki MA; Brault M; Bleakley M
Cancer J; 2019; 25(3):179-190. PubMed ID: 31135525
[TBL] [Abstract][Full Text] [Related]
17. Antigenic Targets for the Immunotherapy of Acute Myeloid Leukaemia.
Khan GN; Orchard K; Guinn BA
J Clin Med; 2019 Jan; 8(2):. PubMed ID: 30678059
[TBL] [Abstract][Full Text] [Related]
18. MUC1-C drives myeloid leukaemogenesis and resistance to treatment by a survivin-mediated mechanism.
Stroopinsky D; Rajabi H; Nahas M; Rosenblatt J; Rahimian M; Pyzer A; Tagde A; Kharbanda A; Jain S; Kufe T; Leaf RK; Anastasiadou E; Bar-Natan M; Orr S; Coll MD; Palmer K; Ephraim A; Cole L; Washington A; Kufe D; Avigan D
J Cell Mol Med; 2018 Aug; 22(8):3887-3898. PubMed ID: 29761849
[TBL] [Abstract][Full Text] [Related]
19. Potential for subsets of wt-NPM1 primary AML blasts to respond to retinoic acid treatment.
Bunaciu RP; MacDonald RJ; Gao F; Johnson LM; Varner JD; Wang X; Nataraj S; Guzman ML; Yen A
Oncotarget; 2018 Jan; 9(3):4134-4149. PubMed ID: 29423110
[TBL] [Abstract][Full Text] [Related]
20. Cathepsin G Is Expressed by Acute Lymphoblastic Leukemia and Is a Potential Immunotherapeutic Target.
Khan M; Carmona S; Sukhumalchandra P; Roszik J; Philips A; Perakis AA; Kerros C; Zhang M; Qiao N; John LSS; Zope M; Goldberg J; Qazilbash M; Jakher H; Clise-Dwyer K; Qiu Y; Mittendorf EA; Molldrem JJ; Kornblau SM; Alatrash G
Front Immunol; 2017; 8():1975. PubMed ID: 29422892
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
